Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SILO with free AI briefings, catalyst countdowns, and dilution alerts.

SILO · Silo Pharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.1M Cash on Hand
34.9mo Cash Runway
Follow SILO by email Get an email when SILO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SILO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

SILO holds $8.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $692,698/quarter from operations, an estimated runway of 34.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 15 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SILO files for a raise →

👥 Who Owns SILO

Insiders 10.1% Institutions 11.7% Public and other holders 78.2%
HolderTypeShares% of sharesAs of
Eric Weisblum
Chief Executive Officer, Director · +387,932 options
Insider 216,932 10.06% 2025-12-15
Mitchell P. Kopin Institution (13G, 5%+) 176,165 8.17% 2026-09-30
AdvisorShares Trust Institution (13G, 5%+) 75,582 3.51% 2026-06-30

Share count 2,156,292 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SILO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SILO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.